Skip to main content
Premium Trial:

Request an Annual Quote

Lucira Health Enters Debt Facility of up to $80M

NEW YORK – Lucira Health said on Tuesday that it has entered into a debt facility of up to $80 million with Hercules Capital and Silicon Valley Bank. 

Under the term loan, Lucira received the first tranche of $30 million at closing on Feb. 4 and will receive a second tranche of $20 million between Sept. 1, 2022, and March 31, 2023, upon achieving certain milestones. A third tranche of $15 million will be available before June 15, 2023, also contingent on certain milestones, while a fourth tranche of $15 million may be available before March 15, 2024, as determined by Hercules and SVB, Lucira said.

The financing will be used to broaden commercial activities and bolster capital reserves, Lucira President and CEO Erik Engelson said in a statement. The company went public in a $153 million stock offering last February.

The firm currently offers its Lucira Check-It COVID-19 test kit, which received Emergency Use Authorization from the US Food and Drug Administration in April 2021, over the counter and its Lucira COVID-19 All-In-One test kit, which nabbed EUA in November 2020, as a prescription test. Both at-home molecular tests use real-time loop-mediated isothermal amplification and are designed to provide results within 30 minutes.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.